Elevation Oncology Inc. is a clinical stage biopharmaceutical company. It focused on the development of precision medicines for patients with genomically defined cancers. Elevation Oncology Inc. is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-44.49M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.48 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -74.68% |
| Return on Assets (Trailing 12 Months) | -48.14% |
| Current Ratio (Most Recent Fiscal Quarter) | 19.40 |
| Quick Ratio (Most Recent Fiscal Quarter) | 19.40 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.67 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.02 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.24 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.78 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.82 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 59.22M |
| Free Float | 54.43M |
| Market Capitalization | $22.61M |
| Average Volume (Last 20 Days) | 2.07M |
| Beta (Past 60 Months) | 1.44 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 83.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |